Cotellic in Combination With Zelboraf Helps People With Specific Advanced Melanoma Live Longer Than With Zelboraf Alone

Genentech, a member of the Roche Group

, announced Saturday, data from the pivotal coBRIM study, which showed that Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer (overall survival; OS) than with Zelboraf alone. Cotellic plus Zelboraf reduced the risk of death by 30 percent compared to Zelboraf alone and helped people live a median of nearly two years (median OS 22.3 months vs. 17.4 months, hazard ratio [HR]=0.70, 95 percent CI: 0.55-0.90, p=0.005). Ongoing study monitoring did not identify any new safety signals. The final coBRIM OS results were presented today during the 12th International Congress of the Society for Melanoma